ADC Therapeutics (ADCT) Enterprise Value (2019 - 2026)

ADC Therapeutics (ADCT) has reported Enterprise Value for 8 consecutive years, with -$231.0 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value fell 18.65% year-over-year to -$231.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.0 million (down 18.65% YoY) and the FY2025 annual result came in at -$261.3 million, down 4.17% from the prior year.
• Enterprise Value advanced to -$231.0 million in Q1 2026 per ADCT's latest filing, from -$261.3 million in the prior quarter.
• Over the last five years, Enterprise Value for ADCT reached as high as -$194.7 million in Q1 2025 and fell as low as -$430.9 million in Q1 2022.
• A 5-year average of -$294.6 million and a median of -$278.6 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 30.03% — and 2026, when it fell 18.65%.
• Year by year, Enterprise Value stood at -$326.4 million in 2022, then rose by 14.66% to -$278.6 million in 2023, then climbed by 9.95% to -$250.9 million in 2024, then retreated by 4.17% to -$261.3 million in 2025, then gained by 11.61% to -$231.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$231.0 million, -$261.3 million, and -$234.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.